Nuvisan logo
  • contact us navContact Us
  • search navSearch

Omics and biomarkers

From target identification to predictive biomarkers
Nuvisan is a leading provider of omics and biomarker solutions, offering comprehensive support for drug discovery. Whether you need assistance with target identification and validation, mode-of-action studies, compound profiling or the identification of pharmacodynamic and predictive biomarkers for patient stratification, our expert team uses advanced technologies to enhance your project and increase its likelihood of success. 

CRISPR/Cas9 system for editing, regulating and targeting genomes

Functional genomics and next-generation sequencing (NGS)

Our cutting-edge functional genomics platform offers versatile tools for drug discovery, including CRISPR/Cas9 genome editing, RNA interference, next-generation sequencing (NGS) and bioinformatics. We provide state-of-the-art NGS and single-cell sequencing technology. Our solutions help identify novel targets and biomarkers and analyse the mode-of-action of compounds with exceptional resolution.

Learn More
Image features a 3D rendering of a double helix structure with blue light emanating from its edges, symbolizing UMIS (Unique Molecular Identifiers) in the field of molecular biology.

Single-cell sequencing

Single-cell sequencing is a breakthrough technology that enables whole-genome gene expression profiling of thousands of cells simultaneously. This advancement in transcriptomics greatly enhances the understanding of disease molecular pathophysiology and compound action. Discover our solutions as a certified 10x Genomics single-cell sequencing service provider.

learn more
Colorful chain of amino acids or proteins - 3d illustration 

Proteomics

Our proteomics team leverages advanced techniques to address the complexities of biological systems, uncovering pathways relevant to disease mechanisms and compound action. We tackle the specific scientific challenges of your drug discovery project, delivering quantitative data to identify pharmacodynamic and predictive biomarkers.

learn more
Laboratory medicine analyzes bodily fluids and tissues to aid in the detection and monitoring of diseases

Biomarker discovery

Our biomarker scientists provide tailored approaches to identify and validate pharmacodynamic, target engagement and selection biomarkers. Biomarkers offer valuable insights into the pharmacokinetic/pharmacodynamic relationships of novel compounds and treatment responses. Profiling our tissue biobank identifies relevant patient populations, while analysing biomarkers from clinical trial samples helps ensure seamless translation of preclinical findings into clinical applications.

Learn More

Frequently asked questions (FAQs)

  • Where in the drug discovery workflow do your omics and biomarker capabilities add the most value?
    Our omics and biomarker capabilities support the full drug discovery workflow, from target identification and validation through mode-of-action (MoA) studies, compound profiling, and selection of pharmacodynamic and predictive biomarkers. We use omics to generate mechanism-based evidence and biomarkers to turn that evidence into measurable readouts that can support later stages of development.
     
  • How do you use functional genomics to strengthen confidence in a target or mechanism?
    We use functional genomics to link gene-level perturbations with relevant cellular phenotypes and pathway changes. This supports target identification and validation, as well as MoA hypotheses. It also helps distinguish causal drivers from downstream effects and provides a stronger basis for target prioritisation and interpretation of compound responses.
  • Why use single-cell RNA sequencing instead of bulk transcriptomics, and what do you deliver?
    Single-cell sequencing profiles thousands of individual cells in parallel and reveals heterogeneity that bulk methods can miss. This includes rare subpopulations, differences in pathway activation and changes in cell state under disease or treatment conditions. As a certified 10x Genomics single-cell sequencing service provider, we generate whole-transcriptome data sets that support understanding of molecular pathophysiology and compound action.
  • What scientific questions is proteomics best suited to answer in drug discovery?
    Proteomics is well suited to mapping pathway-level changes and capturing biology that is closer to functional effectors than RNA alone. We use advanced proteomics to investigate complex biological systems and deliver quantitative data that supports MoA understanding and the identification of pharmacodynamic and predictive biomarkers linked to compound action and disease mechanisms.
  • How do you move from ‘biomarker candidates’ to clinically useful pharmacodynamic or predictive biomarkers?
    We use tailored strategies to identify and validate pharmacodynamic, target engagement and selection biomarkers. These biomarkers help quantify PK/PD relationships and treatment response. Tissue biobank profiling supports the identification of relevant patient populations, while analysis of clinical trial biomarkers supports translation of preclinical findings into clinical application.

Contact us

Nuvisan is committed to protecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. If you consent to us contacting you for this purpose, please tick below to say how you would like us to contact you:
You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Email us

hello@nuvisan.com

Talk to us

talk icon
+49 731 9840 0 

Our locations

location icon

Neu-Ulm (headquarters)

Wegenerstrasse 13

89231 Neu-Ulm

Germany

Berlin

Muellerstrasse 178

13353 Berlin

Germany

Sophia Antipolis

2400 route des Colles

06410 Biot

France

Grafing

Am Feld 32

85567 Grafing

Germany

Waltrop

Im Wirrigen 25

45731 Waltrop

Germany

For concerns about pharmaceuticals or adverse drug-related events, contact us at: complaints@nuvisan.com
 
v.1.1.1387